Christian Bailly (#Oncowitan) has obtained a CIR accreditation (Crédit Impôt Recherche) for three years, by the French Ministry of Higher Education and Research as a R&D consultant. This Research Tax Credit (CIR) agreement is valid for years 2023-2025. The expenses (30%) linked to your Research & Development (R&D) work that you may give me are then officially eligible.
Dr Philippe Verwaerde (CEO of Alzprotect) announced the appointment of Prof. Christian Bailly (#Oncowitan) to the Board of Directors of Alzprotect (Lille, France) to contribute to the development of their drug candidate AZP2006 (Ezeprogind) for Read more…
Christian Bailly (#Oncowitan) received the Prize Michel Delalande 2023, from the National Academy of Pharmacy (Paris, France) on December 13, 2023. A prize awarded for his research activities on anticancer natural products over the past Read more…
Development & Manufacturing of POLYGON therapeutic leader product PLG-101, a monoclonal antibody for the treatment of cardiovascular diseases (myocardial infacrtion). The antibody PLG-101 aims to enhance post-ischemic cardiac remodeling. Christian Bailly (Oncowitan) brings his exertise Read more…